Purpose: Deregulated metabolism in cancer cells represents a vulnerability that may be therapeutically exploited to benefit patients. One such target is nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in the NAD+ salvage pathway. NAMPT is necessary for efficient NAD+ production and may be exploited in cells with increased metabolic demands. We have identified NAMPT as a dependency in rhabdomyosarcoma (RMS), a malignancy for which novel therapies are critically needed. Here we describe the effect of NAMPT inhibition on RMS proliferation and metabolism in vitro and in vivo. Experimental Design: Assays of proliferation and cell death were used to determine the effects of pharmacologic NAMPT inhibition in a panel of ten molecularly diverse RMS cell lines. Mechanism of the clinical NAMPTi OT-82 was determined using measures of NAD+ and downstream NAD+-dependent functions, including energy metabolism. We used orthotopic xenograft models to examine tolerability, efficacy, and drug mechanism in vivo. Results: Across all ten RMS cell lines, OT-82 depleted NAD+ and inhibited cell growth at concentrations ≤1 nmol/L. Significant impairment of glycolysis was a universal finding, with some cell lines also exhibiting diminished oxidative phosphorylation. Most cell lines experienced profound depletion of ATP with subsequent irreversible necrotic cell death. Importantly, loss of NAD and glycolytic activity were confirmed in orthotopic in vivo models, which exhibited complete tumor regressions with OT-82 treatment delivered on the clinical schedule. Conclusions: RMS is highly vulnerable to NAMPT inhibition. These findings underscore the need for further clinical study of this class of agents for this malignancy.
Disruption of DNA damage repair via impaired homologous recombination is characteristic of Ewing sarcoma (EWS) cells. We hypothesize that this disruption results in increased reliance on nonhomologous end joining to repair DNA damage. In this study, we investigated if pharmacologic inhibition of the enzyme responsible for nonhomologous end joining, the DNA-PK holoenzyme, alters the response of EWS cells to genotoxic standard of care chemotherapy. We used analyses of cell viability and proliferation to investigate the effects of clinical DNA-PK inhibitors (DNA-PKi) in combination with six therapeutic or experimental agents for EWS. We performed calculations of synergy using the Loewe additivity model. Immunoblotting evaluated treatment effects on DNA-PK, DNA damage, and apoptosis. Flow cytometric analyses evaluated effects on cell cycle and fate. We used orthotopic xenograft models to interrogate tolerability, drug mechanism, and efficacy in vivo. DNA-PKi demonstrated on-target activity, reducing phosphorylated DNA-PK levels in EWS cells. DNA-PKi sensitized EWS cell lines to agents that function as topoisomerase 2 (TOP2) poisons and enhanced the DNA damage induced by TOP2 poisons. Nanomolar concentrations of single-agent TOP2 poisons induced G2M arrest and little apoptotic response while adding DNA-PKi-mediated apoptosis. In vivo, the combination of AZD7648 and etoposide had limited tolerability but resulted in enhanced DNA damage, apoptosis, and EWS tumor shrinkage. The combination of DNA-PKi with standard of care TOP2 poisons in EWS models is synergistic, enhances DNA damage and cell death, and may form the basis of a promising future therapeutic strategy for EWS.
Adrenocortical carcinoma (ACC) is a rare, aggressive, chemoresistant malignancy with limited effective systemic therapies and few recurrent actionable oncogenic drivers. Although IGF-2 is overexpressed in approximately 80% of ACCs, clinical inhibition of the IGF-1R/InsR axis has not improved outcomes. To identify clinically tractable combination strategies that enhance IGF-1R/InsR inhibition in ACC, we performed a quantitative high-throughput combinatorial screen of 2,803 mechanistically annotated oncology compounds with the IGF 1R/InsR inhibitor linsitinib in an ACC cell line. Downstream effects of IGF-1R/InsR signaling were assessed to identify actionable nodes for combination targeting. Candidate combinations were validated using short-term ACC patient-derived organoids (PDOs) and patient-derived xenograft (PDX) models. The screen identified MAPK pathway inhibitors—particularly MEK inhibition—as the top synergistic partners with IGF-1R/InsR inhibition. Genetic or pharmacologic inhibition of IGF-1R/InsR and MEK signaling suppressed ACC growth in vitro. Downstream profiling of IGF-1R/InsR signaling identified AKT as a major effector, supporting direct AKT targeting as a translatable substitute for IGF-1R/InsR inhibition in ACC. Accordingly, the AKT inhibitor capivasertib synergized with the MEK inhibitor cobimetinib in ACC cell lines and six ACC PDO models. In vivo, combined AKT and MEK inhibition reduced tumor growth more than either agent alone in an ACC xenograft and two ACC chemotherapy-resistant PDX models with acceptable tolerability. These data identify AKT as a critical survival pathway in ACC and support combined AKT and MEK inhibition with FDA-approved agents as a therapeutic approach for chemotherapy-resistant ACC.